Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A. The raise follows a $4M seed in February -- taking its total raised to date to $20M. Put simply, Mogrify's approach entails analysis of vast amounts of genomic data in order to identify the specific energetic changes needed to flip an adult cell from one type to another without having to reset it to a stem cell state -- with huge potential utility for a wide variety of therapeutic use-cases. "What we're trying to do with Mogrify is systematize that process where you can say here's my source cell, here's my target cell, here are the differences between the networks… and here are the most likely points of intervention that we're going to have to make to drive the fate of an adult cell to another adult cell without going through a stem cell stage," says CEO and investor Dr Darrin Disley. So far he says it's successfully converted 15 cells out of 15 tries. "We're now rapidly moving those on through our own programs and partnership programs," he adds.